Thinking of joining a study?

Register your interest

Become a volunteer?

NCT07290205 | RECRUITING | Anesthesia

Remimazolam NeuroImaging
Sponsor:

Keith M Vogt

Information provided by (Responsible Party):

Keith M Vogt

Brief Summary:

This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task

Condition or disease

Anesthesia

Pain

Remimazole

Intervention/treatment

Remimazolam

Peripheral Nerve Stimulation

Phase

EARLY_PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 60 participants
Masking : NONE
Primary Purpose : BASIC_SCIENCE
Official Title : Neuroimaging of Sedation With Remimazolam
Actual Study Start Date : 2026-03-01
Estimated Primary Completion Date : 2027-12-01
Estimated Study Completion Date : 2027-12-02

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 59 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: 1
Criteria
Inclusion Criteria
  • * Adults 18-59 years of age, who:
  • * have none of the specific exclusion criteria
  • * have a valid email address and valid phone number throughout the study
  • * free from any non-MRI compatible implants
Exclusion Criteria
  • * are pregnant or attempting to conceive
  • * body mass index (BMI) \> 35
  • * significant memory impairment or hearing loss
  • * sleep apnea
  • * chronic pain or frequently taking pain medication (including tramadol)
  • * chronic medical conditions requiring treatment (hypertension, diabetes, high cholesterol)
  • * neurologic disease, including seizures and tremor
  • * psychiatric diagnoses, including anxiety, depression, panic, or PTSD
  • * a history of any of these medical conditions: abnormal heartbeats (cardiac conduction abnormality or arrhythmia), liver or kidney disease, or significant lung disease
  • * severe claustrophobia or MRI intolerance
  • * have metal implants or non-removable metal piercings
  • * having a history of adverse reaction to midazolam (Versed), lorazepam (Ativan) or another benzodiazepine class medication
  • * are allergic to dextran
  • * daily alcohol or heavy alcohol use; history of alcohol abuse
  • * current daily smoker
  • * regular or recent marijuana use (including prescribed/medical marijuana)
  • * illicit drug use, i.e., street drugs
  • * regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids
Remimazolam NeuroImaging

Location Details

NCT07290205

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Pennsylvania

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213